Log in to save to my catalogue

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7616743

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to assess how the effects of empagliflozin would evolve after the discontinuation of the trial drug.
In t...

Alternative Titles

Full title

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7616743

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7616743

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2409183

How to access this item